The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals

  1. Margaret E Torrence
  2. Michael R MacArthur
  3. Aaron M Hosios
  4. Alexander J Valvezan
  5. John M Asara
  6. James R Mitchell
  7. Brendan D Manning  Is a corresponding author
  1. Harvard T H Chan School of Public Health, United States
  2. Rutgers Robert Wood Johnson Medical School, United States
  3. Beth Israel Deaconess Medical Center, United States
  4. Swiss Federal Institute of Technology (ETH) Zurich, United States

Abstract

The mechanistic target of rapamycin complex 1 (mTORC1) stimulates a coordinated anabolic program in response to growth-promoting signals. Paradoxically, recent studies indicate that mTORC1 can activate the transcription factor ATF4 through mechanisms distinct from its canonical induction by the integrated stress response (ISR). However, its broader roles as a downstream target of mTORC1 are unknown. Therefore, we directly compared ATF4-dependent transcriptional changes induced upon insulin-stimulated mTORC1 signaling to those activated by the ISR. In multiple mouse embryo fibroblast (MEF) and human cancer cell lines, the mTORC1-ATF4 pathway stimulated expression of only a subset of the ATF4 target genes induced by the ISR, including genes involved in amino acid uptake, synthesis, and tRNA charging. We demonstrate that ATF4 is a metabolic effector of mTORC1 involved in both its established role in promoting protein synthesis and in a previously unappreciated function for mTORC1 in stimulating cellular cystine uptake and glutathione synthesis.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided as supplemental tables for Figures 1, 2, and 3. RNA-Seq data have been deposited in GEO under accession code GSE158605.

The following data sets were generated

Article and author information

Author details

  1. Margaret E Torrence

    Department of Molecular Metabolism, Harvard T H Chan School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
  2. Michael R MacArthur

    Department of Molecular Metabolism, Harvard T H Chan School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
  3. Aaron M Hosios

    Department of Molecular Metabolism, Harvard T H Chan School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
  4. Alexander J Valvezan

    Center for Advanced Biotechnology and Medicine, Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, United States
    Competing interests
    No competing interests declared.
  5. John M Asara

    Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, United States
    Competing interests
    No competing interests declared.
  6. James R Mitchell

    Department of Health Sciences and Technology, Swiss Federal Institute of Technology (ETH) Zurich, Schwerzenbach, United States
    Competing interests
    No competing interests declared.
  7. Brendan D Manning

    Department of Molecular Metabolism, Harvard T H Chan School of Public Health, Boston, United States
    For correspondence
    bmanning@hsph.harvard.edu
    Competing interests
    Brendan D Manning, Brendan Manning is a scientific advisory board member and stockholder of Navitor Pharmaceuticals and LAM Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3895-5956

Funding

National Institutes of Health (R35-CA197459)

  • Brendan D Manning

National Institutes of Health (P01-CA120964)

  • Brendan D Manning

U.S. Department of Defense (W81XWH-18-1- 0659)

  • Brendan D Manning

National Institutes of Health (T32-ES016645)

  • Margaret E Torrence

National Institutes of Health (F31-CA228332)

  • Margaret E Torrence

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Roger J Davis, University of Massachusetts Medical School, United States

Ethics

Animal experimentation: All animal procedures were conducted under strict adherence to recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and were approved by the Harvard Institutional Animal Care and Use Committee (#IS00000780).

Version history

  1. Received: September 22, 2020
  2. Accepted: February 26, 2021
  3. Accepted Manuscript published: March 1, 2021 (version 1)
  4. Version of Record published: March 26, 2021 (version 2)

Copyright

© 2021, Torrence et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 16,663
    views
  • 1,980
    downloads
  • 123
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Margaret E Torrence
  2. Michael R MacArthur
  3. Aaron M Hosios
  4. Alexander J Valvezan
  5. John M Asara
  6. James R Mitchell
  7. Brendan D Manning
(2021)
The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals
eLife 10:e63326.
https://doi.org/10.7554/eLife.63326

Share this article

https://doi.org/10.7554/eLife.63326

Further reading

    1. Cancer Biology
    2. Cell Biology
    Ian Lorimer
    Insight

    Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.

    1. Cancer Biology
    Xia Shen, Xiang Peng ... Chen-Ying Liu
    Research Article

    The role of processing bodies (P-bodies) in tumorigenesis and tumor progression is not well understood. Here, we showed that the oncogenes YAP/TAZ promote P-body formation in a series of cancer cell lines. Mechanistically, both transcriptional activation of the P-body-related genes SAMD4A, AJUBA, and WTIP and transcriptional suppression of the tumor suppressor gene PNRC1 are involved in enhancing the effects of YAP/TAZ on P-body formation in colorectal cancer (CRC) cells. By reexpression of PNRC1 or knockdown of P-body core genes (DDX6, DCP1A, and LSM14A), we determined that disruption of P-bodies attenuates cell proliferation, cell migration, and tumor growth induced by overexpression of YAP5SA in CRC. Analysis of a pancancer CRISPR screen database (DepMap) revealed co-dependencies between YAP/TEAD and the P-body core genes and correlations between the mRNA levels of SAMD4A, AJUBA, WTIP, PNRC1, and YAP target genes. Our study suggests that the P-body is a new downstream effector of YAP/TAZ, which implies that reexpression of PNRC1 or disruption of P-bodies is a potential therapeutic strategy for tumors with active YAP.